Nrx Pharmaceuticals Inc Stock Price, News & Analysis

NRx Pharmaceuticals (NRXP) has appointed Michael Abrams as permanent Chief Financial Officer, replacing Interim-CFO Richard Narido. Abrams brings nearly three decades of experience as an executive officer, investment banker, and senior advisor, including CFO roles at Arch Therapeutics, RiseIT Solutions, and FitLife Brands. He specializes in financial operations, accounting, M&A, and capital raising. Narido will continue supporting the company's financial function and focus on HOPE Therapeutics projects. The appointment aligns with NRx's goal of transitioning from a pre-revenue biotechnology company to a profitable enterprise.

NRx Pharmaceuticals (NRXP) reported significant progress in Q3 2024, with plans to file NDAs for NRX-100 (IV Ketamine) and NRX-101 for treating suicidal ideation in depression by year-end 2024. The company achieved a 74% reduction in net operating losses compared to Q3 2023, reducing from $6.1M to $1.6M. HOPE Therapeutics, their subsidiary, is acquiring Interventional Psychiatry Clinics and expects first revenue by year-end 2024. The company secured $10.8M in convertible-debt funding and forecasts profitability in 2025 from HOPE Therapeutics and medication sales.

NRx Pharmaceuticals (NASDAQ: NRXP) has rescheduled its third quarter and year to date 2024 financial results conference call to Monday, November 18, 2024, at 4:30 PM ET. The change was made to accommodate potential additional corporate news. Investors can access the conference call through a live webcast on the company's website or via telephone using domestic (+1-800-717-1738) or international (+1-646-307-1865) dial-in numbers.

NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its third quarter and year to date 2024 financial results after market close on Thursday, November 14, 2024. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and provide a corporate update. The conference call will be accessible via webcast on the company's website and through telephone dial-in options for both domestic (+1-800-717-1738) and international (+1-646-307-1865) participants.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has signed a non-binding Letter of Intent to acquire Interventional Psychiatry Clinics in Florida. The target clinics are described as top performers, currently generating revenue and positive EBITDA. The acquisition is expected to be immediately accretive to both revenue and EBITDA for HOPE and NRx. These facilities will serve as the foundation for HOPE's expansion in Florida, offering comprehensive mental health services. The company aims to establish HOPE as a model for clinics providing the latest standard of care treatments for CNS healthcare providers nationwide.

NRx Pharmaceuticals (NRXP) and its wholly-owned subsidiary HOPE Therapeutics announced their participation in the upcoming ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will present at 8:30 AM ET. The conference brings together institutional investors, corporate clients, and industry professionals. The NRx management team will conduct one-on-one investor meetings throughout the day. The presentation will be available via live stream on the NRx Events platform.

HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), has announced signing a non-binding Letter of Intent (LOI) to acquire a premier West Coast Interventional Psychiatric Clinic. This acquisition is set to establish HOPE's model for a network of clinics across the country, providing advanced treatments for CNS disorders such as suicidal depression and PTSD.

Key points of the announcement include:

• The clinic's founder, a nationally recognized leader in advanced CNS disorder treatments, will join HOPE as Chief Medical Innovation Officer (CMIO).
• The acquisition is expected to be immediately accretive to revenue and EBITDA for both HOPE and NRx.
• The clinic will serve as a prototype for HOPE's network, offering treatments like Ketamine, Spravato, Transcranial Magnetic Stimulation (TMS), and talk therapy.
• Patients may also gain access to clinical trials of new treatment modalities through these clinics.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has announced the completion of twelve months of stability on the first manufactured commercial scale lot of NRX-100 (Ketamine). This milestone supports the submission of an FDA New Drug Application for the use of intravenous ketamine to treat Suicidal Depression. NRX-100 is the first preservative-free formulation of Ketamine, potentially avoiding toxic side effects of preservatives used in current preparations designed for single dose anesthetic use.

Key points:

• No degradation of the active ingredient was observed during the stability testing
• Projected room temperature shelf stability in excess of three years
• Filing of the NDA for NRX-100 is on track for 2024
• NRX-100 could benefit the 3.8 million people who make a plan to commit suicide in the United States each year

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, was featured in an article on Psychiatrist.com, the home of the Journal of Clinical Psychiatry. The article, titled 'How NRx Could Upend the Fight Against Depression and Suicide,' highlights the company's pipeline products NRX-100 and NRX-101.

NRX-101 is a twice-daily oral combination of D-cycloserine and lurasidone designed to treat suicidal treatment-resistant bipolar depression. Research indicates it may be more effective than lurasidone alone in reducing akathisia and suicidality. NRX-100, a proprietary preservative-free formulation of IV ketamine, is being studied as a treatment for acute suicidal crises in depression.